Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Therapeutic Drug Carrier Systems
Импакт фактор: 2.9 5-летний Импакт фактор: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Печать: 0743-4863
ISSN Онлайн: 2162-660X

Выпуски:
Том 37, 2020 Том 36, 2019 Том 35, 2018 Том 34, 2017 Том 33, 2016 Том 32, 2015 Том 31, 2014 Том 30, 2013 Том 29, 2012 Том 28, 2011 Том 27, 2010 Том 26, 2009 Том 25, 2008 Том 24, 2007 Том 23, 2006 Том 22, 2005 Том 21, 2004 Том 20, 2003 Том 19, 2002 Том 18, 2001 Том 17, 2000 Том 16, 1999 Том 15, 1998 Том 14, 1997 Том 13, 1996 Том 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2018025781
pages 183-217

Inhalational Drug Delivery in Pulmonary Aspergillosis

Ranjot Kaur
University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India 160014; School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, United Kingdom
Ripandeep Kaur
UGC Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh, India 160014
Charan Singh
University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India 160014
Shahdeep Kaur
UGC Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh, India 160014
Amit K. Goyal
Institute of Research and Development, Gujarat Forensic Science University, Gandhinagar, Gujarat, India 382007
Kamalinder K. Singh
School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, United Kingdom
Bhupinder Singh
University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India 160014; UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh, India 160014

Краткое описание

Pulmonary infections have long represented one of the major threats to humans. These vary from acute to chronic conditions, depending upon the underlying disease of the airways. Pulmonary aspergillosis (PMAP) has raised vital concerns in the immunocompromised patients. The fungal infection is difficult to diagnose in the early stages, often making the disease more complicated. Currently, three classes of antifungal agents are available on the market for the treatment of pulmonary infections. These agents are available in oral and intravenous forms only, which limits the availability of therapeutic concentrations of drug in the lungs for longer durations. Consequently, this leads to therapeutic failure and/or resistance of the organism(s) towards the antifungal agents because the optimum amount of drug does not reach the infection site. To combat the issues associated with the conventional regimens, inhalation of antifungal agents is gaining importance because administration to the lungs offers huge advantages of localized and targeted delivery. A wide range of inhalational devices such as nebulizers, dry powder inhalers, and metered dose inhalers are available on the market to deliver drug molecules to the lungs effectively. However, their clinical utility is limited to conditions such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis only. For a few decades, inhalation therapy has also been gaining importance to treat infectious diseases such as tuberculosis and aspergillosis, though more research efforts are required to make the transition from bench to bedside. The current review provides an explicit account of the potential role of inhalation drug delivery in PMAP.


Articles with similar content:

Newer Therapeutic Vistas for Antiglaucoma Medicines
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 2
Shilpa Kakkar, Indu Pal Kaur, Harinder Singh
Colloidal Carriers: A Rising Tool for Therapy of Tuberculosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 4
Suresh P. Vyas, Manish K. Gupta, Swati Gupta, Pankaj Kumar
Nanostructured Delivery Systems: Augmenting the Delivery of Antiretroviral Drugs for Better Management of HIV/AIDS
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 6
Sanaul Mustafa, Roopa S Pai, Gurinder Singh
Nanomedicines for Treatment of Viral Diseases
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 1
Medha Joshi, Vandana B. Patravale, Rujuta Mehendale
Insights into the Approach, Fabrication, Application, and Lacunae of Nanoemulsions in Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.37, 2020, issue 6
Subhabrata Ray, Mahfoozur Rahman, Kumar Anand, Sanmoy Karmakar